Medicus Pharma Highlights Results From Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis; Says Data Reveal 'a clear and consistent dose-response relationship across endpoints'

Medicus Pharma Ltd

MDCX

0.00

200μg Cohort Achieves 55% Complete Response at Day 57 Emerging asRegistrational Grade Lead Regimen

The pre-specified expanded dataset analysis builds on this foundation by:
 Revealing a clear and consistent dose-response relationship across endpoints
 Demonstrating stronger separation between the 200μg cohort and control, particularly at Day 57
 Strengthens differentiation between drug-driven efficacy and device-only biological activity

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.